Psoriatic Arthritis Clinical Trial
— EXCEED 1Official title:
A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis
Verified date | January 2021 |
Source | Novartis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This was a randomized, double-blind, active controlled, multicenter, parallel-group study evaluating secukinumab monotherapy and adalimumab monotherapy in approximately 850 patients with active psoriatic arthritis (PsA) who are naïve to biologic therapy and are intolerant or having inadequate response to conventional disease modifying anti-rheumatic drugs (also known as non-biologic DMARDs).
Status | Completed |
Enrollment | 853 |
Est. completion date | December 30, 2019 |
Est. primary completion date | December 30, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Key Inclusion Criteria: - Diagnosis of PsA classified by CASPAR - Rheumatoid factor and anti-CCP antibodies negative - Diagnosis of active plaque psoriasis, with at least one psoriatic plaque of >= 2cm diameter or nail changes consistent with psoriasis or documented history of plaque psoriasis - Inadequate control of symptoms with NSAIDs - Inadequate control of symptoms with a conventional DMARD. Key Exclusion Criteria: - Pregnant or nursing women - Evidence of ongoing infectious or malignant process - Previous exposure to any biologic drug for Psoriatic Arthritis or Psoriasis - Subjects taking high potency opioid analgesics - Ongoing use of prohibited psoriasis treatments/medications - Previous treatment with any cell-depleting therapies including but not limited to anti-CD20 investigational agents. |
Country | Name | City | State |
---|---|---|---|
Australia | Novartis Investigative Site | Hobart | Tasmania |
Australia | Novartis Investigative Site | Kogarah | New South Wales |
Australia | Novartis Investigative Site | Malvern East | Victoria |
Australia | Novartis Investigative Site | Maroochydore | Queensland |
Bulgaria | Novartis Investigative Site | Pleven | |
Bulgaria | Novartis Investigative Site | Plovdiv | |
Bulgaria | Novartis Investigative Site | Plovdiv | |
Bulgaria | Novartis Investigative Site | Sofia | |
Bulgaria | Novartis Investigative Site | Sofia | |
Canada | Novartis Investigative Site | Trois-Rivieres | Quebec |
Canada | Novartis Investigative Site | Victoria | British Columbia |
Canada | Novartis Investigative Site | Winnipeg | Manitoba |
Czechia | Novartis Investigative Site | Bruntal | |
Czechia | Novartis Investigative Site | Praha 2 | |
Czechia | Novartis Investigative Site | Praha 5 | |
Czechia | Novartis Investigative Site | Uherske Hradiste | |
Czechia | Novartis Investigative Site | Zlin | |
Denmark | Novartis Investigative Site | Frederiksberg | |
Estonia | Novartis Investigative Site | Tallinn | |
Estonia | Novartis Investigative Site | Tallinn | |
Estonia | Novartis Investigative Site | Tartu | |
Finland | Novartis Investigative Site | Hyvinkaa | |
Finland | Novartis Investigative Site | Kuopio | |
France | Novartis Investigative Site | Brive-la-Gaillarde | |
France | Novartis Investigative Site | Cahors | |
France | Novartis Investigative Site | Chambray les Tours | |
France | Novartis Investigative Site | Le Mans | |
France | Novartis Investigative Site | Orleans | |
France | Novartis Investigative Site | Paris | |
France | Novartis Investigative Site | Poitiers | |
Germany | Novartis Investigative Site | Bad Doberan | |
Germany | Novartis Investigative Site | Berlin | |
Germany | Novartis Investigative Site | Berlin | |
Germany | Novartis Investigative Site | Berlin | |
Germany | Novartis Investigative Site | Berlin | |
Germany | Novartis Investigative Site | Bochum | |
Germany | Novartis Investigative Site | Erlangen | |
Germany | Novartis Investigative Site | Hamburg | |
Germany | Novartis Investigative Site | Herne | |
Germany | Novartis Investigative Site | Leipzig | |
Germany | Novartis Investigative Site | Magdeburg | |
Germany | Novartis Investigative Site | Osnabruck | |
Germany | Novartis Investigative Site | Schwerin | |
Greece | Novartis Investigative Site | Athens | |
Greece | Novartis Investigative Site | Athens | |
Greece | Novartis Investigative Site | Thessaloniki | |
Hungary | Novartis Investigative Site | Budapest | |
Hungary | Novartis Investigative Site | Budapest | |
Hungary | Novartis Investigative Site | Budapest | |
Hungary | Novartis Investigative Site | Debrecen | |
Hungary | Novartis Investigative Site | Gyor | |
Hungary | Novartis Investigative Site | Kistarcsa | |
Hungary | Novartis Investigative Site | Veszprem | |
Iceland | Novartis Investigative Site | Reykjavik | |
India | Novartis Investigative Site | Mumbai | Maharashtra |
India | Novartis Investigative Site | Nashik | Maharashtra |
India | Novartis Investigative Site | New Delhi | |
India | Novartis Investigative Site | Secunderabad | Telangana |
Israel | Novartis Investigative Site | Haifa | |
Israel | Novartis Investigative Site | Haifa | |
Israel | Novartis Investigative Site | Haifa | |
Israel | Novartis Investigative Site | Kfar Saba | |
Israel | Novartis Investigative Site | Petach Tikva | |
Israel | Novartis Investigative Site | Ramat Gan | |
Israel | Novartis Investigative Site | Tel Aviv | |
Italy | Novartis Investigative Site | Arenzano | GE |
Italy | Novartis Investigative Site | Bologna | |
Italy | Novartis Investigative Site | Pisa | |
Italy | Novartis Investigative Site | Rozzano | MI |
Italy | Novartis Investigative Site | Torino | |
Italy | Novartis Investigative Site | Verona | VR |
Korea, Republic of | Novartis Investigative Site | Seoul | Seocho Gu |
Latvia | Novartis Investigative Site | Riga | |
Latvia | Novartis Investigative Site | Valmiera | |
Lithuania | Novartis Investigative Site | Kaunas | LTU |
Lithuania | Novartis Investigative Site | Klaipeda | |
Lithuania | Novartis Investigative Site | Siauliai | |
Netherlands | Novartis Investigative Site | Enschede | |
Netherlands | Novartis Investigative Site | Sneek | |
Poland | Novartis Investigative Site | Dopiewo | |
Poland | Novartis Investigative Site | Szczecin | |
Poland | Novartis Investigative Site | Warszawa | |
Poland | Novartis Investigative Site | Warszawa | |
Portugal | Novartis Investigative Site | Lisboa | |
Portugal | Novartis Investigative Site | Lisboa | |
Portugal | Novartis Investigative Site | Ponte de Lima | |
Portugal | Novartis Investigative Site | Porto | |
Portugal | Novartis Investigative Site | Porto | |
Russian Federation | Novartis Investigative Site | Ekaterinburg | |
Russian Federation | Novartis Investigative Site | Kemerovo | |
Russian Federation | Novartis Investigative Site | Kemerovo | |
Russian Federation | Novartis Investigative Site | Moscow | |
Russian Federation | Novartis Investigative Site | Moscow | |
Russian Federation | Novartis Investigative Site | Nizhny Novgorod | |
Russian Federation | Novartis Investigative Site | Petrozavodsk | |
Russian Federation | Novartis Investigative Site | Rostov on Don | |
Russian Federation | Novartis Investigative Site | Smolensk | |
Russian Federation | Novartis Investigative Site | Yaroslavl | |
Slovakia | Novartis Investigative Site | Bratislava | |
Slovakia | Novartis Investigative Site | Kosice | |
Slovakia | Novartis Investigative Site | Partizanske | |
Slovakia | Novartis Investigative Site | Topolcany | |
Spain | Novartis Investigative Site | Badalona | Barcelona |
Spain | Novartis Investigative Site | Baracaldo | Vizcaya |
Spain | Novartis Investigative Site | Barcelona | |
Spain | Novartis Investigative Site | Barcelona | Catalunya |
Spain | Novartis Investigative Site | Bilbao | Pais Vasco |
Spain | Novartis Investigative Site | Cordoba | Andalucia |
Spain | Novartis Investigative Site | L Hospitalet De Llobregat | Barcelona |
Spain | Novartis Investigative Site | La Coruna | Galicia |
Spain | Novartis Investigative Site | La Laguna | Santa Cruz De Tenerife |
Spain | Novartis Investigative Site | Madrid | |
Spain | Novartis Investigative Site | Madrid | |
Spain | Novartis Investigative Site | Malaga | Andalucia |
Spain | Novartis Investigative Site | Merida | Extremadura |
Spain | Novartis Investigative Site | Sabadell | Barcelona |
Spain | Novartis Investigative Site | Santander | Cantabria |
Spain | Novartis Investigative Site | Santiago de Compostela | Galicia |
Spain | Novartis Investigative Site | Sevilla | |
Spain | Novartis Investigative Site | Sevilla | Andalucia |
Spain | Novartis Investigative Site | Valencia | |
Spain | Novartis Investigative Site | Valencia | Comunidad Valenciana |
United Kingdom | Novartis Investigative Site | Cannock | Staffordshire |
United Kingdom | Novartis Investigative Site | Edinburgh | |
United Kingdom | Novartis Investigative Site | Glasgow | |
United Kingdom | Novartis Investigative Site | Hull | |
United Kingdom | Novartis Investigative Site | Leytonstone | London |
United Kingdom | Novartis Investigative Site | London | |
United Kingdom | Novartis Investigative Site | London | |
United Kingdom | Novartis Investigative Site | Newcastle Upon Tyne | |
United Kingdom | Novartis Investigative Site | Plymouth | |
United Kingdom | Novartis Investigative Site | Salford | Manchester |
United Kingdom | Novartis Investigative Site | Solihull | |
United Kingdom | Novartis Investigative Site | Stoke on Trent | Staffordshire |
United Kingdom | Novartis Investigative Site | Torquay | Devon |
United Kingdom | Novartis Investigative Site | Wigan | |
United Kingdom | Novartis Investigative Site | Wolverhampton | |
United States | Novartis Investigative Site | Arlington | Texas |
United States | Novartis Investigative Site | Austin | Texas |
United States | Novartis Investigative Site | Bethlehem | Pennsylvania |
United States | Novartis Investigative Site | Bowling Green | Kentucky |
United States | Novartis Investigative Site | Burlington | Vermont |
United States | Novartis Investigative Site | Dallas | Texas |
United States | Novartis Investigative Site | Duncansville | Pennsylvania |
United States | Novartis Investigative Site | Fountain Valley | California |
United States | Novartis Investigative Site | Fullerton | California |
United States | Novartis Investigative Site | Glendale | Wisconsin |
United States | Novartis Investigative Site | La Mesa | California |
United States | Novartis Investigative Site | Lincoln | Nebraska |
United States | Novartis Investigative Site | Mesquite | Texas |
United States | Novartis Investigative Site | Omaha | Nebraska |
United States | Novartis Investigative Site | Rochester | New York |
United States | Novartis Investigative Site | Saint Louis | Missouri |
United States | Novartis Investigative Site | Seattle | Washington |
United States | Novartis Investigative Site | Spokane | Washington |
United States | Novartis Investigative Site | Upland | California |
Lead Sponsor | Collaborator |
---|---|
Novartis Pharmaceuticals |
United States, Australia, Bulgaria, Canada, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, India, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Slovakia, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 52 | Clinical response, failure to permanently discontinue study medication prematurely, and lack of need for rescue medication was required for a patient to achieve treatment success. The primary endpoint is the proportion of patients with monotherapy ACR20 response at Week 52 where monotherapy ACR20 response is defined as meeting the following 3 conditions:
achieving American College of Rheumatology 20 (ACR20) response no permanent study treatment (secukinumab or adalimumab) discontinuation before or at Week 50 (the last dosing visit) no use of conventional disease modifying anti-rheumatic drugs (also known as non-biologic DMARDs) cDMARDs (including Methotrexate (MTX)) after Week 36 (regardless of the starting time of taking cDMARDs) |
Week 52 | |
Secondary | Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI)-90 Response at Week 52 | The PASI is a system used for assessing and grading the severity of psoriatic lesions. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 to 6, and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants who achieved at least a 90 percent improvement from baseline in the PASI score. | Week 52 | |
Secondary | Percentage of Participants Who Achieved an American College of Rheumatology 50% (ACR50) Response at Week 52 | Clinical response, failure to permanently discontinue study medication prematurely, and lack of need for rescue medication was required for a patient to achieve treatment success. The secondary endpoint is the proportion of patients with monotherapy ACR50 response at Week 52 where monotherapy ACR50 response is defined as meeting the following 3 conditions:
achieving American College of Rheumatology 50 (ACR50) response no permanent study treatment (secukinumab or adalimumab) discontinuation before or at Week 52 no use of conventional disease modifying anti-rheumatic drugs (also known as non-biologic DMARDs) cDMARDs (including Methotrexate (MTX)) after Week 36 (regardless of the starting time of taking cDMARDs) |
Week 52 | |
Secondary | Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI Score) at Week 52 | The HAQ-DI assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in 8 categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip and usual activities. The stem of each item asks 'Over the past week, "are you able to..." perform a particular task'. Each item is scored on a 4 point scale from 0 - 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) and unable to do (3). The disability index score is calculated as the mean of the available category scores, ranging from 0 to 3. A negative change from baseline indicates improvement. | Baseline, Week 52 | |
Secondary | Percentage of Participants Who Achieved Resolution of Enthesitis at Week 52 | Enthesitis refers to inflammation of entheses, the site where ligaments or tendons insert into the bones. Resolution was defined as the absence of recorded enthesitis; conducted by the study assessor. | Week 52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04152759 -
Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT01925768 -
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
|
Phase 3 | |
Completed |
NCT01892436 -
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
|
Phase 3 | |
Completed |
NCT01212770 -
PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
|
Phase 3 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Completed |
NCT01212757 -
PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
|
Phase 3 | |
Completed |
NCT03953378 -
CD73+ Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis
|
||
Recruiting |
NCT02572700 -
Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis
|
||
Completed |
NCT02556034 -
Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA.
|
||
Completed |
NCT02154425 -
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
|
Phase 1 | |
Completed |
NCT02188654 -
Metformin in Psoriatic Arthritis
|
N/A | |
Completed |
NCT01392326 -
Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)
|
Phase 3 | |
Completed |
NCT02164214 -
Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)?
|
Phase 3 | |
Completed |
NCT01083693 -
Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
|
N/A | |
Not yet recruiting |
NCT00517101 -
Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy
|
N/A | |
Completed |
NCT00133315 -
TNFalfa Blocking Treatment of Spondylarthropathies
|
Phase 4 | |
Completed |
NCT00659412 -
A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis
|
Phase 2 | |
Completed |
NCT00946686 -
To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions
|
Phase 1 | |
Not yet recruiting |
NCT06059430 -
Cohort Project of Patients With Inflammatory Rheumatism
|